Erzotabart

DB19063InvestigationalProtein Based Therapies

Erzotabart is under investigation in clinical trial NCT04824794 (GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies).

Mechanism
Curator reviewed
Also known as
gamma1 heavy chain Homo sapiens (1-450) [VH (Homo sapiens IGHV1-69*04 (93.8%) -(IGHD) -IGHJ3*02 (93.8%), CDR-IMGT [8.8.14] (26-33.51-58.97-110)) (1-121)-Homo sapiens IGHG1*03, G1m3, nG1m1 CH1 R120 CH3 E12, M14, IGHG1v34 CH3 G109 (CH1 R120 (218) (122-219) · Immunoglobulin g1 (434-glycine), anti-(human cd38 antigen) (human monoclonal gen3014 .gamma.1-chain), disulfide with human monoclonal gen3014 .kappa.-chain, dimer · Immunoglobulin G1-kappa, anti-[Homo sapiens CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1)], Homo sapiens monoclonal antibody
Code names
GEN-3014

Resolves to

Compound
UNII1I9AVY2IS7CAS2430792-01-9
Targets
P28907CD38

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Erzotabart, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In